Immunotherapy trial offers hope for advanced cancer patients out of options
NCT ID NCT02628067
Summary
This study tested an immunotherapy drug called pembrolizumab in people with many different types of advanced solid tumors that had stopped responding to standard treatments. The main goal was to see if the drug could shrink tumors and to identify biological markers that might predict who would benefit most. Over 1,600 participants with cancers like cervical, lung, thyroid, and others were enrolled to receive the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.